Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21232Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Agouridis, A. P. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:13:51Z | - |
| dc.date.available | 2015-11-24T19:13:51Z | - |
| dc.identifier.issn | 1558-9307 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21232 | - |
| dc.rights | Default Licence | - |
| dc.subject | Dyslipidemias/*drug therapy/*metabolism | en |
| dc.subject | Fatty Acids, Omega-3/*metabolism | en |
| dc.subject | Female | en |
| dc.subject | Fenofibrate/*therapeutic use | en |
| dc.subject | Fluorobenzenes/*therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hypolipidemic Agents/*therapeutic use | en |
| dc.subject | Male | en |
| dc.subject | Pyrimidines/*therapeutic use | en |
| dc.subject | Sulfonamides/*therapeutic use | en |
| dc.title | High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1007/s11745-011-3538-0 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21327725 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/8145g0557336512l/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | The aim of the study was to compare the efficacy of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega-3 fatty acids with regard to the lipid profile in patients with mixed hyperlipidemia. The primary endpoint was changes in non-high density lipoprotein-cholesterol (non-HDL-C) levels. Study participants were randomly allocated to receive rosuvastatin 40 mg (n = 30, R group), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 30, RF group) or rosuvastatin 10 mg plus n-3 fatty acids 2 g (n = 30, RN group). Non-HDL-C levels were reduced in all groups: in R group by 54%, in RF group by 42% and in RN group by 42%. Significant reductions in total cholesterol (TC), low density lipoprotein (LDL)-C and triglyceride levels were observed in all groups. The reductions in total and LDL-C were greatest in the R group while a more pronounced reduction of triglycerides in the RF group compared with that in the R and the RN group was observed. HDL-C levels were significantly increased only in the RF group. In conclusion, high doses of rosuvastatin and small doses of rosuvastatin plus either fenofibrate or n-3 fatty acids exhibit favorable effects on both LDL-C and non-HDL-C levels. However, rosuvastatin monotherapy more potently reduces these parameters. The combination of rosuvastatin plus fenofibrate leads to a greater decrease in triglyceride levels and a greater increase in HDL-C levels compared with the other two treatments. While awaiting the results of ongoing trials high doses of rosuvastatin may represent the treatment of choice in individuals with mixed dyslipidemia. | en |
| heal.journalName | Lipids | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Agouridis-2011-High doses of rosuva.pdf | 235.92 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
